Component: (Network and Table)
Network
00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS
(http://www.tabularasahealthcare.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001651561 (http://www.sec.gov/CIK)
Statement of Cash Flows [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Statement of Cash Flows [Abstract]
 
 
 
Cash flows from operating activities:
 
 
 
Net loss
(6,250,000) 
(2,864,000) 
(1,107,000) 
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 
 
Depreciation and amortization
5,115,000  
3,933,000  
1,817,000  
Amortization of deferred financing costs and debt discount
1,279,000  
2,148,000  
259,000  
Payment of imputed interest on debt
(3,893,000) 
(105,000) 
(13,000) 
Deferred taxes
498,000  
290,000  
(422,000) 
Issuance of common stock warrants
 
16,000  
31,000  
Stock-based compensation
4,250,000  
565,000  
254,000  
Change in fair value of warrant liability
(639,000) 
2,786,000  
269,000  
Change in fair value of acquisition-related contingent consideration
(338,000) 
(2,059,000) 
790,000  
Change in fair value of acquisition-related consideration
55,000  
  
Loss on extinguishment of debt
6,411,000  
  
Write-off in-process software development costs
  
63,000  
Other noncash items
 
(10,000) 
 
Changes in operating assets and liabilities, net of effect from acquisitions:
 
 
 
Accounts receivable, net
(633,000) 
(1,711,000) 
(1,388,000) 
Inventories
(607,000) 
(264,000) 
(792,000) 
Rebates receivable
752,000  
(96,000) 
(715,000) 
Prepaid expenses and other current assets
(929,000) 
(259,000) 
(77,000) 
Other assets
1,000  
(4,000) 
(30,000) 
Acquisition-related contingent consideration
 
(610,000) 
(60,000) 
Accounts payable
665,000  
440,000  
1,383,000  
Accrued expenses and other liabilities
(1,168,000) 
1,060,000  
604,000  
Other long-term liabilities
2,205,000  
 
4,000  
Net cash provided by operating activities
6,774,000  
 
3,256,000  
 
870,000  
 
Cash flows from investing activities:
 
 
 
Purchases of property and equipment
(3,813,000) 
(234,000) 
(230,000) 
Software development costs
(1,854,000) 
(940,000) 
(738,000) 
Purchase of intangible assets
(29,000) 
  
Change in restricted cash
200,000  
300,000  
(500,000) 
Purchase of businesses, net of cash acquired
(5,400,000) 
(2,403,000) 
(13,448,000) 
Net cash used in investing activities
(10,896,000) 
 
(3,277,000) 
 
(14,916,000) 
 
Cash flows from financing activities:
 
 
 
Proceeds from exercise of stock options
153,000  
12,000  
59,000  
Payments for debt financing costs
(1,521,000) 
(69,000) 
(212,000) 
Proceeds from notes payable to related parties
  
100,000  
Repayments of notes payable to related parties
(250,000) 
(354,000) 
(175,000) 
Borrowings on line of credit
6,000,000  
10,000,000  
 
Repayments of line of credit
(16,000,000) 
(6,860,000) 
 
Payments of acquisition-related consideration
(180,000) 
(1,895,000) 
(487,000) 
Repayment of note payable related to acquisition
(14,337,000) 
  
Payments of initial public offering costs
(3,346,000) 
(481,000) 
 
Payments of contingent consideration
(1,895,000) 
(267,000) 
(440,000) 
Proceeds from long-term debt
30,000,000  
 
15,000,000  
Repayments of long-term debt
(47,369,000) 
(2,161,000) 
(1,704,000) 
Proceeds from issuance of common stock under initial public offering, net of underwriting costs
55,186,000  
  
Net cash provided by (used in) financing activities
6,441,000  
 
(2,075,000) 
 
12,141,000  
 
Net increase (decrease) in cash
2,319,000  
 
(2,096,000) 
 
(1,905,000) 
 
Cash, beginning of period
2,026,000  
4,122,000  
6,027,000  
Cash, end of period
4,345,000  
 
2,026,000  
 
4,122,000  
 
Supplemental disclosure of cash flow information
 
 
 
Acquisition of equipment under capital leases
1,605,000  
373,000  
326,000  
Additions to property, equipment, and software development purchases included in accounts payable
373,000  
46,000  
53,000  
Deferred offering costs included in accounts payable
132,000  
1,817,000  
 
Cash paid for interest
8,457,000  
2,409,000  
1,080,000  
(Decretion) accretion of redeemable convertible preferred stock to redemption value
(2,439,000) 
9,966,000  
3,884,000  
Fair value of promissory notes entered into connection with Medliance acquisition
  
14,347,000  
Fair value of preferred stock warrants issued to lender
  
1,835,000